Marketed in 35 countries across Europe, Asia-Pacific, Latin America, and parts of Africa, Adalat is a globally distributed brand of nifedipine, classified pharmacologically as a calcium channel blocker. The page is written for travellers, expatriates, and family members trying to understand whether a medication they know from home is the same product they have just been handed at a pharmacy abroad — or vice versa.
Nifedipine is prescribed in the management of hypertension and angina pectoris, and is also indicated in the context of certain coronary events and in Raynaud disease. Its pharmacological profile spans antihypertensive, antianginal, and vasodilator activity, and the structured indication section further down this page lists the registered uses recognised across the markets where Adalat is authorised.
Because Adalat is registered in so many jurisdictions, travellers frequently encounter the same medication abroad — sometimes still labelled as Adalat, sometimes as a nifedipine-containing generic, and sometimes under another brand entirely. Markets where Adalat is sold include Brazil, China, Germany, Australia, and Egypt, but regulatory packaging, available formulations, and prescription pathways vary considerably from one country to another. A pharmacist in any of these markets can confirm whether a locally available nifedipine product is the right substitute for the one a patient knows from home.
Other medications within the calcium channel blocker class are sold in many of the same markets under different molecules and different brand names, and several are widely used in cardiovascular care. Molecules within a class are not freely interchangeable, however, and switching between them is a clinical decision rather than a pharmacy-counter one. Anyone taking Adalat, considering it, or trying to identify a local equivalent should make that decision together with a qualified healthcare provider.
